Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Мультисистемный эффект цитопротекции
Мультисистемный эффект цитопротекции
Ларина В.Н. Мультисистемный эффект цитопротекции. Consilium Medicum. 2021; 23 (1): 93–98. DOI: 10.26442/20751753.2021.1.200732
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье обсуждаются антиишемические и плейотропные эффекты лекарственного препарата из группы миокардиальных цитопротекторов – триметазидина. В настоящее время триметазидин рекомендован специалистами научных медицинских сообществ в качестве эффективного антиангинального препарата для лечения пациентов разного возраста с диагнозом «стабильная стенокардия». Триметазидин, обратимый конкурентный ингибитор 3-кетоацил-кофермента А тиолазы, имеет хороший профиль безопасности и переносимости, улучшает физическую работоспособность у пациентов со стабильной стенокардией и ишемической кардиомиопатией и рассматривается в качестве средства, влияющего на энергетический метаболизм клеток в условиях ишемии, оптимизирующего использование кислорода миокардом за счет усиления аэробного гликолиза и уменьшения интенсивности окисления свободных жирных кислот. Результаты исследования VASCO-angina позволяют рассматривать суточную дозу триметазидина 70 мг как стандартную терапевтическую при лечении пациентов с ишемической болезнью сердца. Исследование КАРДИОКАНОН подтвердило клиническую эквивалентность оригинального и воспроизводимого препарата триметазидин – Депренорм® МВ (производитель ЗАО «Канонфарма продакшн», Россия) при вторичной профилактике ишемической болезни сердца и ее осложнений. Плейотропные эффекты: антиатеросклеротический, противовоспалительный, нефропротективный, нейропротективный – позволяют расширить применение триметазидина в клинической практике.
Ключевые слова: ишемическая болезнь сердца, стенокардия напряжения, метаболизм, ишемия, триметазидин
Keywords: coronary artery disease, angina pectoris, metabolism, ischemia, trimetazidine
Ключевые слова: ишемическая болезнь сердца, стенокардия напряжения, метаболизм, ишемия, триметазидин
________________________________________________
Keywords: coronary artery disease, angina pectoris, metabolism, ischemia, trimetazidine
Полный текст
Список литературы
1. Российское кардиологическое общество. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2020. Рос. кардиол. журн. 2020; 25 (11): 4076 [Rossiiskoe kardiologicheskoe obshchestvo. Stabil'naia ishemicheskaia bolezn' serdtsa. Klinicheskie rekomendatsii 2020. Ros. kardiol. zhurn. 2020; 25 (11): 4076 (in Russian)]. DOI: 10.15829/29/1560-4071-2020-4076
2. Формулировка патологоанатомического диагноза при ишемической болезни сердца (класс IX «Болезни системы кровообращения» МКБ-10). В кн.: Клинические рекомендации RPS4.9.1(2016). М.: Практическая медицина, 2016 [Formulirovka patologoanatomicheskogo diagnoza pri ishemicheskoi bolezni serdtsa (klass IX "Bolezni sistemy krovoobrashcheniia" MKB-10). V kn.: Klinicheskie rekomendatsii RPS4.9.1(2016). Moscow: Prakticheskaia meditsina, 2016 (in Russian)].
3. Knuuti J, Wijns W, Saraste A, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (3): 407–77. DOI: 10.1093/eurheartj/ehz425
4. Timmis A, Townsend N, Gale C, et al. Atlas Writing Group. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018; 39 (7): 508–79. DOI: 10.1093/eurheartj/ehx628
5. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol 2018; 72 (21): 2625–41. DOI: 10.1016/j.jacc.2018.09.042
6. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41 (37): 3504–20. DOI: 10.1093/eurheartj/ehaa503
7. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Ключевые недостатки вторичной профилактики ишемической болезни сердца с помощью лекарственной терапии: роль комбинированных препаратов с постоянными дозами в решении проблемы. Кардиология. 2018; 58 (11): 17–23 [Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M. Key drawbacks of secondary ischemic heart disease prevention with drug therapy: the role of combination fixed dose preparations in solution of this problem. Kardiologiia. 2018; 58 (11): 17–23 (in Russian)].
DOI: 10.18087/cardio.2018.11.10194
8. Wu L, Luan Y, Li Y, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord 2020; 20 (1): 273. DOI: 10.1186/s12872-020-01557-3
9. Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol 2019; 293: 39–44. DOI: 10.1016/j.ijcard.2019.05.06
10. Di Pasquale P, Verso Lo P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 1999; 13: 423–8.
11. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris – executive summary. The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
12. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25 (20): 1814–21. DOI: 10.1016/j.ehj.2004.06.034
13. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing hear. Physiol Rev 2005; 85 (3): 1093–129.
14. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4: CD003614. DOI: 10.1002/14651858.CD003614.pub2
15. Szwed Н, Sadowski Z, Elikowski W, et al. Trimpol II: combination treatment of stable effort angina using trimetazidine and metoprolol: results of а randomised, double blind, multicentre study. Eur Heart J 2001; 22 (2): 2267–74.
16. Сизова Ж.М., Владимиров С.К. Современные возможности миокардиальной цитопротекции в лечении больных ишемической болезнью сердца. Мед. совет. 2016; 13: 38–43 [Sizova Zh.M., Vladimirov S.K. Sovremennye vozmozhnosti miokardial'noi tsitoprotektsii v lechenii bol'nykh ishemicheskoi bolezn'iu serdtsa. Med. sovet. 2016; 13: 38–43 (in Russian)].
17. Jiang L. Rehabilitation medicine department, Xiangya hospital, Trimetazidine combined with exercise improves anti-stress capacity through enhancing autophagy and apoptosis of myocardium in mice. Eur Heart J 2020; 41 (Suppl. 2). DOI: 10.1093/ehjci/ehaa946.3099
18. Krüger K, Reichel T, Zeilinger C. Role of heat shock proteins 70/90 in exercise physiology and exercise immunology and their diagnostic potential in sports. J Appl Physiol (1985) 2019; 126 (4): 916–27. DOI: 10.1152/japplphysiol.01052.2018
19. Шилов А.М. Место препаратов с метаболической направленностью в условиях первичного звена здравоохранения при профилактике и лечении ишемических синдромов. Мед. совет. 2015; 2: 60–5 [Shilov A.M. Mesto preparatov s metabolicheskoi napravlennost'iu v usloviiakh pervichnogo zvena zdravookhraneniia pri profilaktike i lechenii ishemicheskikh sindromov. Med. sovet. 2015; 2: 60–5 (in Russian)].
20. Lochner A, Genade S, Genis A, et al. Long-chain free fatty acids inhibit ischaemic preconditioning of the isolated rat heart. Mol Cell Biochem 2020; 473 (1–2): 111–32. DOI: 10.1007/s11010-020-03812-9
21. Карпова Э.С., Котельникова Е.В., Лямина Н.П. Ишемическое прекондиционирование и его кардиопротективный эффект в программах кардиореабилитации больных с ишемической болезнью сердца после чрескожных коронарных вмешательств. Рос. кардиол. журн. 2012; 4: 104–8 [Karpova E.S., Kotelnikova E.V., Lyamina N.P. Ischemic preconditioning and its cardioprotective effect in post-intervention cardiac rehabilitation programmes for patients with coronary heart disease. Russian Journal of Cardiology. 2012; 4: 104–8 (in Russian)].
22. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol 2013; 168 (2): 1078–81. DOI: 10.1016/j.ijcard.2012.11.001
23. Чекулдаева Л.Е., Обухова С.В., Симаков А.А., и др. Проблема взаимозаменяемости лекарственных препаратов. Триметазидин МВ – эффективная терапия больных ишемической болезнью сердца. Рациональная фармакотерапия в кардиологии. 2012; 8 (4): 515–20 [Chekuldaeva L.E., Obuhova S.V., Simakov A.A., et al. The problem of interchangeability of drug products. trimetazidine is an effective treatment of patients with ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2012; 8 (4): 515–20 (in Russian)]. DOI: 10.20996/1819-6446-2012-8-4-515-520
24. Сизова Ж.М. Взаимозаменяемость миокардиальных цитопротекторов в лечении больных с ишемической болезнью сердца. Трудные вопросы – простые решения. Рациональная фармакотерапия в кардиологии. 2013; 9 (2): 183–7 [Sizova Z.M. Interchangeability of myocardial cytoprotectors in patients with ischemic heart disease. Difficult questions – simple solutions. Rational Pharmacotherapy in Cardiology. 2013; 9 (2): 183–7 (in Russian)]. DOI: 10.20996/1819-6446-2013-9-2-183-187
25. Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная фармакотерапия в кардиологии. 2012; 8 (2): 179–84 [Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L., et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacotherapy in Cardiology. 2012;
8 (2): 179–84 (in Russian)]. DOI: 10.20996/1819-6446-2012-8-2-54-55
26. Körnicke T, Arora D, Samad A, et al. Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine – Modified Release in Healthy Human Subjects. Drug Res (Stuttg) 2020; 70 (10): 472–7. DOI: 10.1055/a-1180-4357
27. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93 (6): 703–7.
28. Ромащенко О.В., Клочкова Г.Н., Муханова Е.И., Гайворонская И.В. Плейотропные эффекты триметазидина. Рос. кардиол. журн. 2013; 4: 83–7 [Romashchenko O.V., Klochkova G.N., Mukhanova E.I., Gaivoronskaia I.V. Pleiotropnye effekty trimetazidina. Ros. kardiol. zhurn. 2013; 4: 83–7 (in Russian)].
29. Mahfoudh-Boussaid A, Hadj-Ayed K, Zaouali MA, et al. Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail 2014; 36 (9): 1436–42.
30. Ibrahim TA, El-Mawardy RH, El-Serafy AS, El-Fekky EM. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med 2017; 18 (5): 315–9. DOI: 10.1016/j.carrev.2017.02.006
31. Hassanzadeh G, Hosseini A, Pasbakhsh P, et al. Trimetazidine Prevents Oxidative Changes Induced in a Rat Model of Sporadic Type Of Alzheimer’s Disease. Acta Med Iran 2015; 53 (1): 17–24.
32. Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol 2014; 114 (3): 389–94. DOI: 10.1016/j.amjcard.2014.04.052
33. Гиляров М.Ю., Константинова Е.В., Ковалец П.В., и др. Какие факторы ассоциированы с развитием контраст-индуцированной нефропатии у пациентов старческого возраста с острым коронарным синдромом в реальной клинической практике? Рациональная фармакотерапия в кардиологии. 2020; 16 (6): 908–15 [Gilyarov M.Yu., Konstantinova E.V., Kovalets P.V., et al. What factors are associated with the development of contras-induced nephropathy in elderly patients with acute coronary syndrome in real clinical practice? Rational pharmacotherapy in cardiology. 2020; 16 (6): 908–15 (in Russian)]. DOI: 10.20996/1819-6446-2020-12-02
34. Аронов Д.М. Консенсус экспертов о роли и месте миокардиального цитопротектора триметазидина (Предуктала МВ) в терапии больных с хроническими формами ишемической болезни сердца. Сердце. 2015; 14 (4): 256–60 [Aronov D.M. Konsensus ekspertov o roli i meste miokardial'nogo tsitoprotektora trimetazidina (Preduktala MV) v terapii bol'nykh s khronicheskimi formami ishemicheskoi bolezni serdtsa. Serdtse. 2015; 14 (4): 256–60 (in Russian)].
35. Клинические рекомендации. Хроническая сердечная недостаточность. Категория: взрослые. 2020 [Clinical guidelines. Chronic heart failure. Category: adults. 2020 (in Russian)].
DOI: 10.15829/29/1560-4071-2020-4076
2. Formulirovka patologoanatomicheskogo diagnoza pri ishemicheskoi bolezni serdtsa (klass IX "Bolezni sistemy krovoobrashcheniia" MKB-10). V kn.: Klinicheskie rekomendatsii RPS4.9.1(2016). Moscow: Prakticheskaia meditsina, 2016 (in Russian)
3. Knuuti J, Wijns W, Saraste A, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (3): 407–77. DOI: 10.1093/eurheartj/ehz425
4. Timmis A, Townsend N, Gale C, et al. Atlas Writing Group. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018; 39 (7): 508–79. DOI: 10.1093/eurheartj/ehx628
5. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol 2018; 72 (21): 2625–41. DOI: 10.1016/j.jacc.2018.09.042
6. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41 (37): 3504–20. DOI: 10.1093/eurheartj/ehaa503
7. Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M. Key drawbacks of secondary ischemic heart disease prevention with drug therapy: the role of combination fixed dose preparations in solution of this problem. Kardiologiia. 2018; 58 (11): 17–23 (in Russian)
DOI: 10.18087/cardio.2018.11.10194
8. Wu L, Luan Y, Li Y, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord 2020; 20 (1): 273. DOI: 10.1186/s12872-020-01557-3
9. Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol 2019; 293: 39–44. DOI: 10.1016/j.ijcard.2019.05.06
10. Di Pasquale P, Verso Lo P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 1999; 13: 423–8.
11. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris – executive summary. The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
12. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25 (20): 1814–21. DOI: 10.1016/j.ehj.2004.06.034
13. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing hear. Physiol Rev 2005; 85 (3): 1093–129.
14. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4: CD003614. DOI: 10.1002/14651858.CD003614.pub2
15. Szwed Н, Sadowski Z, Elikowski W, et al. Trimpol II: combination treatment of stable effort angina using trimetazidine and metoprolol: results of а randomised, double blind, multicentre study. Eur Heart J 2001; 22 (2): 2267–74.
16. Sizova Zh.M., Vladimirov S.K. Sovremennye vozmozhnosti miokardial'noi tsitoprotektsii v lechenii bol'nykh ishemicheskoi bolezn'iu serdtsa. Med. sovet. 2016; 13: 38–43 (in Russian)
17. Jiang L. Rehabilitation medicine department, Xiangya hospital, Trimetazidine combined with exercise improves anti-stress capacity through enhancing autophagy and apoptosis of myocardium in mice. Eur Heart J 2020; 41 (Suppl. 2). DOI: 10.1093/ehjci/ehaa946.3099
18. Krüger K, Reichel T, Zeilinger C. Role of heat shock proteins 70/90 in exercise physiology and exercise immunology and their diagnostic potential in sports. J Appl Physiol (1985) 2019; 126 (4): 916–27. DOI: 10.1152/japplphysiol.01052.2018
19. Shilov A.M. Mesto preparatov s metabolicheskoi napravlennost'iu v usloviiakh pervichnogo zvena zdravookhraneniia pri profilaktike i lechenii ishemicheskikh sindromov. Med. sovet. 2015; 2: 60–5 (in Russian)
20. Lochner A, Genade S, Genis A, et al. Long-chain free fatty acids inhibit ischaemic preconditioning of the isolated rat heart. Mol Cell Biochem 2020; 473 (1–2): 111–32. DOI: 10.1007/s11010-020-03812-9
21. Karpova E.S., Kotelnikova E.V., Lyamina N.P. Ischemic preconditioning and its cardioprotective effect in post-intervention cardiac rehabilitation programmes for patients with coronary heart disease. Russian Journal of Cardiology. 2012; 4: 104–8 (in Russian)
22. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol 2013; 168 (2): 1078–81. DOI: 10.1016/j.ijcard.2012.11.001
23. Chekuldaeva L.E., Obuhova S.V., Simakov A.A., et al. The problem of interchangeability of drug products. trimetazidine is an effective treatment of patients with ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2012; 8 (4): 515–20 (in Russian). DOI: 10.20996/1819-6446-2012-8-4-515-520
24. Sizova Z.M. Interchangeability of myocardial cytoprotectors in patients with ischemic heart disease. Difficult questions – simple solutions. Rational Pharmacotherapy in Cardiology. 2013; 9 (2): 183–7 (in Russian) DOI: 10.20996/1819-6446-2013-9-2-183-187
25. Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L., et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacotherapy in Cardiology. 2012; 8 (2): 179–84 (in Russian)
DOI: 10.20996/1819-6446-2012-8-2-54-55
26. Körnicke T, Arora D, Samad A, et al. Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine – Modified Release in Healthy Human Subjects. Drug Res (Stuttg) 2020; 70 (10): 472–7. DOI: 10.1055/a-1180-4357
27. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93 (6): 703–7.
28. Romashchenko O.V., Klochkova G.N., Mukhanova E.I., Gaivoronskaia I.V. Pleiotropnye effekty trimetazidina. Ros. kardiol. zhurn. 2013; 4: 83–7 (in Russian)
29. Mahfoudh-Boussaid A, Hadj-Ayed K, Zaouali MA, et al. Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail 2014; 36 (9): 1436–42.
30. Ibrahim TA, El-Mawardy RH, El-Serafy AS, El-Fekky EM. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med 2017; 18 (5): 315–9. DOI: 10.1016/j.carrev.2017.02.006
31. Hassanzadeh G, Hosseini A, Pasbakhsh P, et al. Trimetazidine Prevents Oxidative Changes Induced in a Rat Model of Sporadic Type Of Alzheimer’s Disease. Acta Med Iran 2015; 53 (1): 17–24.
32. Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol 2014; 114 (3): 389–94. DOI: 10.1016/j.amjcard.2014.04.052
33. Gilyarov M.Yu., Konstantinova E.V., Kovalets P.V., et al. What factors are associated with the development of contras-induced nephropathy in elderly patients with acute coronary syndrome in real clinical practice? Rational pharmacotherapy in cardiology. 2020; 16 (6): 908–15 (in Russian) DOI: 10.20996/1819-6446-2020-12-02
34. Aronov D.M. Konsensus ekspertov o roli i meste miokardial'nogo tsitoprotektora trimetazidina (Preduktala MV) v terapii bol'nykh s khronicheskimi formami ishemicheskoi bolezni serdtsa. Serdtse. 2015; 14 (4): 256–60 (in Russian)
35. Clinical guidelines. Chronic heart failure. Category: adults. 2020 (in Russian)
2. Формулировка патологоанатомического диагноза при ишемической болезни сердца (класс IX «Болезни системы кровообращения» МКБ-10). В кн.: Клинические рекомендации RPS4.9.1(2016). М.: Практическая медицина, 2016 [Formulirovka patologoanatomicheskogo diagnoza pri ishemicheskoi bolezni serdtsa (klass IX "Bolezni sistemy krovoobrashcheniia" MKB-10). V kn.: Klinicheskie rekomendatsii RPS4.9.1(2016). Moscow: Prakticheskaia meditsina, 2016 (in Russian)].
3. Knuuti J, Wijns W, Saraste A, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (3): 407–77. DOI: 10.1093/eurheartj/ehz425
4. Timmis A, Townsend N, Gale C, et al. Atlas Writing Group. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018; 39 (7): 508–79. DOI: 10.1093/eurheartj/ehx628
5. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol 2018; 72 (21): 2625–41. DOI: 10.1016/j.jacc.2018.09.042
6. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41 (37): 3504–20. DOI: 10.1093/eurheartj/ehaa503
7. Гиляревский С.Р., Голшмид М.В., Кузьмина И.М. Ключевые недостатки вторичной профилактики ишемической болезни сердца с помощью лекарственной терапии: роль комбинированных препаратов с постоянными дозами в решении проблемы. Кардиология. 2018; 58 (11): 17–23 [Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M. Key drawbacks of secondary ischemic heart disease prevention with drug therapy: the role of combination fixed dose preparations in solution of this problem. Kardiologiia. 2018; 58 (11): 17–23 (in Russian)].
DOI: 10.18087/cardio.2018.11.10194
8. Wu L, Luan Y, Li Y, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord 2020; 20 (1): 273. DOI: 10.1186/s12872-020-01557-3
9. Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol 2019; 293: 39–44. DOI: 10.1016/j.ijcard.2019.05.06
10. Di Pasquale P, Verso Lo P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 1999; 13: 423–8.
11. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris – executive summary. The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
12. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25 (20): 1814–21. DOI: 10.1016/j.ehj.2004.06.034
13. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing hear. Physiol Rev 2005; 85 (3): 1093–129.
14. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4: CD003614. DOI: 10.1002/14651858.CD003614.pub2
15. Szwed Н, Sadowski Z, Elikowski W, et al. Trimpol II: combination treatment of stable effort angina using trimetazidine and metoprolol: results of а randomised, double blind, multicentre study. Eur Heart J 2001; 22 (2): 2267–74.
16. Сизова Ж.М., Владимиров С.К. Современные возможности миокардиальной цитопротекции в лечении больных ишемической болезнью сердца. Мед. совет. 2016; 13: 38–43 [Sizova Zh.M., Vladimirov S.K. Sovremennye vozmozhnosti miokardial'noi tsitoprotektsii v lechenii bol'nykh ishemicheskoi bolezn'iu serdtsa. Med. sovet. 2016; 13: 38–43 (in Russian)].
17. Jiang L. Rehabilitation medicine department, Xiangya hospital, Trimetazidine combined with exercise improves anti-stress capacity through enhancing autophagy and apoptosis of myocardium in mice. Eur Heart J 2020; 41 (Suppl. 2). DOI: 10.1093/ehjci/ehaa946.3099
18. Krüger K, Reichel T, Zeilinger C. Role of heat shock proteins 70/90 in exercise physiology and exercise immunology and their diagnostic potential in sports. J Appl Physiol (1985) 2019; 126 (4): 916–27. DOI: 10.1152/japplphysiol.01052.2018
19. Шилов А.М. Место препаратов с метаболической направленностью в условиях первичного звена здравоохранения при профилактике и лечении ишемических синдромов. Мед. совет. 2015; 2: 60–5 [Shilov A.M. Mesto preparatov s metabolicheskoi napravlennost'iu v usloviiakh pervichnogo zvena zdravookhraneniia pri profilaktike i lechenii ishemicheskikh sindromov. Med. sovet. 2015; 2: 60–5 (in Russian)].
20. Lochner A, Genade S, Genis A, et al. Long-chain free fatty acids inhibit ischaemic preconditioning of the isolated rat heart. Mol Cell Biochem 2020; 473 (1–2): 111–32. DOI: 10.1007/s11010-020-03812-9
21. Карпова Э.С., Котельникова Е.В., Лямина Н.П. Ишемическое прекондиционирование и его кардиопротективный эффект в программах кардиореабилитации больных с ишемической болезнью сердца после чрескожных коронарных вмешательств. Рос. кардиол. журн. 2012; 4: 104–8 [Karpova E.S., Kotelnikova E.V., Lyamina N.P. Ischemic preconditioning and its cardioprotective effect in post-intervention cardiac rehabilitation programmes for patients with coronary heart disease. Russian Journal of Cardiology. 2012; 4: 104–8 (in Russian)].
22. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol 2013; 168 (2): 1078–81. DOI: 10.1016/j.ijcard.2012.11.001
23. Чекулдаева Л.Е., Обухова С.В., Симаков А.А., и др. Проблема взаимозаменяемости лекарственных препаратов. Триметазидин МВ – эффективная терапия больных ишемической болезнью сердца. Рациональная фармакотерапия в кардиологии. 2012; 8 (4): 515–20 [Chekuldaeva L.E., Obuhova S.V., Simakov A.A., et al. The problem of interchangeability of drug products. trimetazidine is an effective treatment of patients with ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2012; 8 (4): 515–20 (in Russian)]. DOI: 10.20996/1819-6446-2012-8-4-515-520
24. Сизова Ж.М. Взаимозаменяемость миокардиальных цитопротекторов в лечении больных с ишемической болезнью сердца. Трудные вопросы – простые решения. Рациональная фармакотерапия в кардиологии. 2013; 9 (2): 183–7 [Sizova Z.M. Interchangeability of myocardial cytoprotectors in patients with ischemic heart disease. Difficult questions – simple solutions. Rational Pharmacotherapy in Cardiology. 2013; 9 (2): 183–7 (in Russian)]. DOI: 10.20996/1819-6446-2013-9-2-183-187
25. Марцевич С.Ю., Кутишенко Н.П., Гинзбург М.Л., и др. Исследование КАРДИОКАНОН: способ решения вопроса о клинической эквивалентности оригинальных и воспроизведенных препаратов. Рациональная фармакотерапия в кардиологии. 2012; 8 (2): 179–84 [Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L., et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacotherapy in Cardiology. 2012;
8 (2): 179–84 (in Russian)]. DOI: 10.20996/1819-6446-2012-8-2-54-55
26. Körnicke T, Arora D, Samad A, et al. Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine – Modified Release in Healthy Human Subjects. Drug Res (Stuttg) 2020; 70 (10): 472–7. DOI: 10.1055/a-1180-4357
27. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93 (6): 703–7.
28. Ромащенко О.В., Клочкова Г.Н., Муханова Е.И., Гайворонская И.В. Плейотропные эффекты триметазидина. Рос. кардиол. журн. 2013; 4: 83–7 [Romashchenko O.V., Klochkova G.N., Mukhanova E.I., Gaivoronskaia I.V. Pleiotropnye effekty trimetazidina. Ros. kardiol. zhurn. 2013; 4: 83–7 (in Russian)].
29. Mahfoudh-Boussaid A, Hadj-Ayed K, Zaouali MA, et al. Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail 2014; 36 (9): 1436–42.
30. Ibrahim TA, El-Mawardy RH, El-Serafy AS, El-Fekky EM. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med 2017; 18 (5): 315–9. DOI: 10.1016/j.carrev.2017.02.006
31. Hassanzadeh G, Hosseini A, Pasbakhsh P, et al. Trimetazidine Prevents Oxidative Changes Induced in a Rat Model of Sporadic Type Of Alzheimer’s Disease. Acta Med Iran 2015; 53 (1): 17–24.
32. Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol 2014; 114 (3): 389–94. DOI: 10.1016/j.amjcard.2014.04.052
33. Гиляров М.Ю., Константинова Е.В., Ковалец П.В., и др. Какие факторы ассоциированы с развитием контраст-индуцированной нефропатии у пациентов старческого возраста с острым коронарным синдромом в реальной клинической практике? Рациональная фармакотерапия в кардиологии. 2020; 16 (6): 908–15 [Gilyarov M.Yu., Konstantinova E.V., Kovalets P.V., et al. What factors are associated with the development of contras-induced nephropathy in elderly patients with acute coronary syndrome in real clinical practice? Rational pharmacotherapy in cardiology. 2020; 16 (6): 908–15 (in Russian)]. DOI: 10.20996/1819-6446-2020-12-02
34. Аронов Д.М. Консенсус экспертов о роли и месте миокардиального цитопротектора триметазидина (Предуктала МВ) в терапии больных с хроническими формами ишемической болезни сердца. Сердце. 2015; 14 (4): 256–60 [Aronov D.M. Konsensus ekspertov o roli i meste miokardial'nogo tsitoprotektora trimetazidina (Preduktala MV) v terapii bol'nykh s khronicheskimi formami ishemicheskoi bolezni serdtsa. Serdtse. 2015; 14 (4): 256–60 (in Russian)].
35. Клинические рекомендации. Хроническая сердечная недостаточность. Категория: взрослые. 2020 [Clinical guidelines. Chronic heart failure. Category: adults. 2020 (in Russian)].
________________________________________________
DOI: 10.15829/29/1560-4071-2020-4076
2. Formulirovka patologoanatomicheskogo diagnoza pri ishemicheskoi bolezni serdtsa (klass IX "Bolezni sistemy krovoobrashcheniia" MKB-10). V kn.: Klinicheskie rekomendatsii RPS4.9.1(2016). Moscow: Prakticheskaia meditsina, 2016 (in Russian)
3. Knuuti J, Wijns W, Saraste A, et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41 (3): 407–77. DOI: 10.1093/eurheartj/ehz425
4. Timmis A, Townsend N, Gale C, et al. Atlas Writing Group. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018; 39 (7): 508–79. DOI: 10.1093/eurheartj/ehx628
5. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol 2018; 72 (21): 2625–41. DOI: 10.1016/j.jacc.2018.09.042
6. Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41 (37): 3504–20. DOI: 10.1093/eurheartj/ehaa503
7. Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M. Key drawbacks of secondary ischemic heart disease prevention with drug therapy: the role of combination fixed dose preparations in solution of this problem. Kardiologiia. 2018; 58 (11): 17–23 (in Russian)
DOI: 10.18087/cardio.2018.11.10194
8. Wu L, Luan Y, Li Y, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord 2020; 20 (1): 273. DOI: 10.1186/s12872-020-01557-3
9. Marzilli M, Vinereanu D, Lopaschuk G, et al. Trimetazidine in cardiovascular medicine. Int J Cardiol 2019; 293: 39–44. DOI: 10.1016/j.ijcard.2019.05.06
10. Di Pasquale P, Verso Lo P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther 1999; 13: 423–8.
11. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris – executive summary. The Task Force on the Management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341–81.
12. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 25 (20): 1814–21. DOI: 10.1016/j.ehj.2004.06.034
13. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing hear. Physiol Rev 2005; 85 (3): 1093–129.
14. Ciapponi A, Pizarro R, Harrison J. Trimetazidine for stable angina. Cochrane Database Syst Rev 2005; 4: CD003614. DOI: 10.1002/14651858.CD003614.pub2
15. Szwed Н, Sadowski Z, Elikowski W, et al. Trimpol II: combination treatment of stable effort angina using trimetazidine and metoprolol: results of а randomised, double blind, multicentre study. Eur Heart J 2001; 22 (2): 2267–74.
16. Sizova Zh.M., Vladimirov S.K. Sovremennye vozmozhnosti miokardial'noi tsitoprotektsii v lechenii bol'nykh ishemicheskoi bolezn'iu serdtsa. Med. sovet. 2016; 13: 38–43 (in Russian)
17. Jiang L. Rehabilitation medicine department, Xiangya hospital, Trimetazidine combined with exercise improves anti-stress capacity through enhancing autophagy and apoptosis of myocardium in mice. Eur Heart J 2020; 41 (Suppl. 2). DOI: 10.1093/ehjci/ehaa946.3099
18. Krüger K, Reichel T, Zeilinger C. Role of heat shock proteins 70/90 in exercise physiology and exercise immunology and their diagnostic potential in sports. J Appl Physiol (1985) 2019; 126 (4): 916–27. DOI: 10.1152/japplphysiol.01052.2018
19. Shilov A.M. Mesto preparatov s metabolicheskoi napravlennost'iu v usloviiakh pervichnogo zvena zdravookhraneniia pri profilaktike i lechenii ishemicheskikh sindromov. Med. sovet. 2015; 2: 60–5 (in Russian)
20. Lochner A, Genade S, Genis A, et al. Long-chain free fatty acids inhibit ischaemic preconditioning of the isolated rat heart. Mol Cell Biochem 2020; 473 (1–2): 111–32. DOI: 10.1007/s11010-020-03812-9
21. Karpova E.S., Kotelnikova E.V., Lyamina N.P. Ischemic preconditioning and its cardioprotective effect in post-intervention cardiac rehabilitation programmes for patients with coronary heart disease. Russian Journal of Cardiology. 2012; 4: 104–8 (in Russian)
22. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina--the VASCO-angina study. Int J Cardiol 2013; 168 (2): 1078–81. DOI: 10.1016/j.ijcard.2012.11.001
23. Chekuldaeva L.E., Obuhova S.V., Simakov A.A., et al. The problem of interchangeability of drug products. trimetazidine is an effective treatment of patients with ischemic heart disease. Rational Pharmacotherapy in Cardiology. 2012; 8 (4): 515–20 (in Russian). DOI: 10.20996/1819-6446-2012-8-4-515-520
24. Sizova Z.M. Interchangeability of myocardial cytoprotectors in patients with ischemic heart disease. Difficult questions – simple solutions. Rational Pharmacotherapy in Cardiology. 2013; 9 (2): 183–7 (in Russian) DOI: 10.20996/1819-6446-2013-9-2-183-187
25. Martsevich S.Yu., Kutishenko N.P., Ginzburg M.L., et al. The KARDIOKANON study: a way to settle the subject of clinical equivalence of generic and original drugs. Rational Pharmacotherapy in Cardiology. 2012; 8 (2): 179–84 (in Russian)
DOI: 10.20996/1819-6446-2012-8-2-54-55
26. Körnicke T, Arora D, Samad A, et al. Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine – Modified Release in Healthy Human Subjects. Drug Res (Stuttg) 2020; 70 (10): 472–7. DOI: 10.1055/a-1180-4357
27. Bonello L, Sbragia P, Amabile N, et al. Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention. Heart 2007; 93 (6): 703–7.
28. Romashchenko O.V., Klochkova G.N., Mukhanova E.I., Gaivoronskaia I.V. Pleiotropnye effekty trimetazidina. Ros. kardiol. zhurn. 2013; 4: 83–7 (in Russian)
29. Mahfoudh-Boussaid A, Hadj-Ayed K, Zaouali MA, et al. Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail 2014; 36 (9): 1436–42.
30. Ibrahim TA, El-Mawardy RH, El-Serafy AS, El-Fekky EM. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med 2017; 18 (5): 315–9. DOI: 10.1016/j.carrev.2017.02.006
31. Hassanzadeh G, Hosseini A, Pasbakhsh P, et al. Trimetazidine Prevents Oxidative Changes Induced in a Rat Model of Sporadic Type Of Alzheimer’s Disease. Acta Med Iran 2015; 53 (1): 17–24.
32. Shehata M. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention. Am J Cardiol 2014; 114 (3): 389–94. DOI: 10.1016/j.amjcard.2014.04.052
33. Gilyarov M.Yu., Konstantinova E.V., Kovalets P.V., et al. What factors are associated with the development of contras-induced nephropathy in elderly patients with acute coronary syndrome in real clinical practice? Rational pharmacotherapy in cardiology. 2020; 16 (6): 908–15 (in Russian) DOI: 10.20996/1819-6446-2020-12-02
34. Aronov D.M. Konsensus ekspertov o roli i meste miokardial'nogo tsitoprotektora trimetazidina (Preduktala MV) v terapii bol'nykh s khronicheskimi formami ishemicheskoi bolezni serdtsa. Serdtse. 2015; 14 (4): 256–60 (in Russian)
35. Clinical guidelines. Chronic heart failure. Category: adults. 2020 (in Russian)
Авторы
В.Н. Ларина*
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*larinav@mail.ru
Pirogov Russian National Research Medical University, Moscow, Russia
*larinav@mail.ru
ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
*larinav@mail.ru
________________________________________________
Pirogov Russian National Research Medical University, Moscow, Russia
*larinav@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.